Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 117,367	$ 136,377
Restricted cash	110	110
Prepaid expenses	5,107	2,488
Research and development rebate receivable	610	1,072
Other current assets	201	1,193
Total current assets	123,395	141,240
Deposit on investment in equity securities	2,700	0
Other assets	629	22
Total Assets	126,724	141,262
Current liabilities
Accounts payable	1,653	1,717
Accrued expenses	117	204
Payroll liabilities	1,071	1,184
Other current liabilities	27	21
Total current liabilities	2,868	3,126
Total Liabilities	2,868	3,126
Commitments and contingencies (Note 14)
Stockholders' equity
Series B convertible preferred stock - $0.001 par value; 10,000 shares authorized; 1 share issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock - $0.18 par value; 175,000 shares authorized; 126,624 shares issued and outstanding as of September 30, 2022 and December 31, 2021	22,792	22,792
Additional paid-in capital - common stock	249,239	243,996
Accumulated deficit	(148,703)	(129,234)
Accumulated other comprehensive loss	(54)	0
Total Stockholders' Equity	123,856	138,136
Total Liabilities and Stockholders' Equity	126,724	141,262
Series B Preferred Stock [Member]
Stockholders' equity
Additional paid-in capital - Series B convertible preferred stock	$ 582	$ 582